ALNY vs RVMD
Alnylam Pharmaceuticals, Inc. and Revolution Medicines, Inc., both Healthcare
Alnylam Pharmaceuticals, Inc. is the larger company at $37B against $35B. Over the past year RVMD returned +517% against -45% for ALNY. Ryufin's sector-relative Smart Score puts RVMD ahead, 10/10 against 8/10.
| Figure | ALNY | RVMD |
|---|---|---|
| Last close | $239 | $216 |
| Market cap | $37B | $35B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 121.3 | n/a |
| 1-year return | -45% | +517% |
| 5-year return | +34% | +635% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alnylam Pharmaceuticals, Inc.
Revenue of $2.5B in H1 2026, net income $370M. Its largest reported line is Amvuttra, 63% of the disclosed total.
Revolution Medicines, Inc.
Open these two in the interactive comparison to add more names, change the period or read the correlation.